1:1 Bonus Issue Recommended: Small Cap Stock Surges 151% In 6-Months

Agriculture sector small cap stock, Indo Us Bio-Tech on July 7, 2023 recommended bonus share in the proportion of 1:1 that implies shareholders will receive 1 bonus share for every 1 share held as on the record date. The stock offered a massive 345% return in last 1-year. Last trading price of Indo Us Bio-Tech stock is Rs 354.00 per share on BSE. Check details below:

Indo Us Bio-Tech Announces Bonus Share: According to the BSE filing of Indo Us Bio-Tech dated July 7, 2023, "Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we here by inform you that the Board recommended the Bonus Issue of Equity Shares in the proportion of 1 (One) Equity Share of Rs, 10/- each for every 1 (one) Equity Shares of Re 10/- each held by the shareholders of the Company as on the record date."

Indo Us Bio-Tech Stock Outlook & Return Over Years: Last trading price of Indo Us Bio-Tech share is Rs 354.00 apiece with marginal intraday gain of 0.30%. The stock's 52-week high price is Rs 369.95 apiece and 52-week low price is Rs 65.10 apiece, respectively. The company has a market capitalisation of Rs 354.92 crore. Indo Us Bio-Tech shares offered attractive return to investors in the last few years. Indo Us Bio-Tech shares delivered 137% return YTD, 345% return in last 1-year, 578% return in last 2-years, and 761% return in last 3-years. In last 5-years, it jumped 913%.

Indo Us Bio-Tech About: The company is involved in crop research & development throw breeding, production of seeds, processing, packing and marketing of high performing hybrid and open pollinated varieties of agricultural crops. (seed testing, soil & water testing). Indo-Us Bio-Tech Limited is engaged in multi-disciplinary crop improvement research programmes, according to its official website.

Disclaimer: The stock just highlights the bonus and is not a recommendation to buy, sell or hold. We have not done fundamental or technical analysis and have no opinion on the stock mentioned. Neither, the author nor Greynium Information Technologies should be held liable for ay losses. Please consult a professional advisor.